Tom Houben

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2605678/publications.pdf Version: 2024-02-01



TOM HOUREN

#	Article	IF	CITATIONS
1	Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick type C1 disease. Journal of Lipid Research, 2022, 63, 100167.	2.0	1
2	Insulin resistance is positively associated with plasma cathepsin D activity in NAFLD patients. Biomolecular Concepts, 2021, 12, 110-115.	1.0	2
3	The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial. Antioxidants, 2021, 10, 129.	2.2	4
4	Myosteatosis in NAFLD patients correlates with plasma Cathepsin D. Biomolecular Concepts, 2021, 12, 27-35.	1.0	7
5	Anti-Inflammatory Effects of Dietary Plant Stanol Supplementation Are Largely Dependent on the Intake of Cholesterol in a Mouse Model of Metabolic Inflammation. Biomedicines, 2021, 9, 518.	1.4	3
6	Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice. Frontiers in Immunology, 2021, 12, 675535.	2.2	13
7	Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Frontiers in Immunology, 2021, 12, 716357.	2.2	8
8	Cysteamine Decreases Lowâ€Ðensity Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Lowâ€Đensity Lipoprotein Receptor–Deficient Mice. Journal of the American Heart Association, 2021, 10, e017524.	1.6	11
9	Glial contribution to cyclodextrin-mediated reversal of cholesterol accumulation in murine NPC1-deficient neurons in vivo. Neurobiology of Disease, 2021, 158, 105469.	2.1	6
10	OxLDL as an Inducer of a Metabolic Shift in Cancer Cells. Journal of Cancer, 2021, 12, 5817-5824.	1.2	5
11	Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia, 2020, 63, 374-384.	2.9	15
12	Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions. Diabetes and Vascular Disease Research, 2020, 17, 147916411989214.	0.9	6
13	Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals. Frontiers in Endocrinology, 2020, 11, 575070.	1.5	15
14	The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells, 2020, 9, 1679.	1.8	197
15	Sexâ€opposed inflammatory effects of 27â€hydroxycholesterol are mediated via differences in estrogen signaling. Journal of Pathology, 2020, 251, 429-439.	2.1	9
16	Nonalcoholic Fatty Liver Disease. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	6
17	Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease. Journal of Lipid Research, 2020, 61, 830-839.	2.0	5
18	Inflammatory Bowel Disease: A Stressed "Gut/Feeling― Cells, 2019, 8, 659.	1.8	61

Tom Houben

#	Article	IF	CITATIONS
19	Hematopoietic Npc1 mutation shifts gut microbiota composition in Ldlrâ^'/â^' mice on a high-fat, high-cholesterol diet. Scientific Reports, 2019, 9, 14956.	1.6	3
20	Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague–Dawley Rats. Biomolecules, 2019, 9, 171.	1.8	17
21	Comment on Tauriainen et al.: Serum, liver and bile sitosterol and sitostanol in obese patients with and without NAFLD. Bioscience Reports, 2018, 38, .	1.1	4
22	Exogenously Added Oxyphytosterols Do Not Affect Macrophageâ€Mediated Inflammatory Responses. Lipids, 2018, 53, 457-462.	0.7	5
23	Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease. Frontiers in Immunology, 2018, 9, 3089.	2.2	8
24	Cathepsin D regulates lipid metabolism in murine steatohepatitis. Scientific Reports, 2017, 7, 3494.	1.6	47
25	Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. Journal of Lipid Research, 2017, 58, 1399-1416.	2.0	94
26	Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation. Scientific Reports, 2017, 7, 12550.	1.6	25
27	Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in LdIr-/- Mice. PLoS ONE, 2016, 11, e0167199.	1.1	3
28	Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Scientific Reports, 2016, 6, 38278.	1.6	35
29	Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlrâ^'/â^' mice. Atherosclerosis, 2016, 255, 59-65.	0.4	25
30	MSP is a negative regulator of inflammation and lipogenesis in ex vivo models of non-alcoholic steatohepatitis. Experimental and Molecular Medicine, 2016, 48, e258-e258.	3.2	17
31	Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS ONE, 2016, 11, e0163843.	1.1	13
32	Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice. International Journal of Molecular Sciences, 2015, 16, 21056-21069.	1.8	17
33	Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis. Biomarkers in Medicine, 2015, 9, 1301-1309.	0.6	5
34	Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlrâ^'/â^' mice. Journal of Hepatology, 2015, 62, 430-436.	1.8	25
35	Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation. American Journal of Gastroenterology, 2015, 110, 462-470.	0.2	40
36	The immunity–diet–microbiota axis in the development of metabolic syndrome. Current Opinion in Lipidology, 2015, 26, 73-81.	1.2	41

#	Article	IF	CITATIONS
37	Bone marrowâ€specific caspaseâ€1/11 deficiency inhibits atherosclerosis development in <i>Ldlr</i> ^{<i>â^'/â^'</i>} mice. FEBS Journal, 2015, 282, 2327-2338.	2.2	60